Last updated: 19 November 2021 at 10:24am EST

Mark Stejbach Net Worth




The estimated Net Worth of Mark Stejbach is at least $165 Thousand dollars as of 26 May 2020. Mr. Stejbach owns over 2,051 units of Flexion Therapeutics Inc stock worth over $18,849 and over the last 13 years he sold FLXN stock worth over $0. In addition, he makes $146,184 as Independent Director at Flexion Therapeutics Inc.

Mr. Stejbach FLXN stock SEC Form 4 insiders trading

Mark has made over 27 trades of the Flexion Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 2,051 units of FLXN stock worth $19,997 on 26 May 2020.

The largest trade he's ever made was exercising 18,000 units of Flexion Therapeutics Inc stock on 1 December 2015 worth over $311,400. On average, Mark trades about 3,492 units every 65 days since 2012. As of 26 May 2020 he still owns at least 2,051 units of Flexion Therapeutics Inc stock.

You can see the complete history of Mr. Stejbach stock trades at the bottom of the page.





Mark Stejbach biography

Mark P. Stejbach serves as Independent Director of the Company. Mr. Stejbach joined our board of directors in 2016. Mr. Stejbach previously served as Senior Vice President and Chief Commercial Officer at Alkermes plc, a publicly traded global biopharmaceutical company, from 2012 to 2018. He currently serves as a senior commercial advisor to EIP Pharma LLC. Mr. Stejbach has over 30 years of experience in biotech and pharmaceuticals, including senior roles in a broad range of commercial functions including marketing, sales, economic affairs, managed care and finance. Prior to his role at Alkermes, Mr. Stejbach served as the Chief Commercial Officer at Tengion, Inc. from 2008 to 2012 and previously held senior positions at Merck and Biogen. Mark received his M.B.A. from the Wharton School, University of Pennsylvania and a B.S. in mathematics from Virginia Tech. Our Board believes that Mr. Stejbach’s executive and operational experience in the pharmaceutical industry and commercial expertise qualifies him to serve on our Board of Directors.

What is the salary of Mark Stejbach?

As the Independent Director of Flexion Therapeutics Inc, the total compensation of Mark Stejbach at Flexion Therapeutics Inc is $146,184. There are 9 executives at Flexion Therapeutics Inc getting paid more, with Michael Clayman having the highest compensation of $3,777,360.



How old is Mark Stejbach?

Mark Stejbach is 57, he's been the Independent Director of Flexion Therapeutics Inc since 2016. There are 9 older and 6 younger executives at Flexion Therapeutics Inc. The oldest executive at Flexion Therapeutics Inc is Samuel Colella, 80, who is the Independent Director.

What's Mark Stejbach's mailing address?

Mark's mailing address filed with the SEC is C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON, MA, 01803.

Insiders trading at Flexion Therapeutics Inc

Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon, and Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.



What does Flexion Therapeutics Inc do?

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.



What does Flexion Therapeutics Inc's logo look like?

Flexion Therapeutics Inc logo

Complete history of Mr. Stejbach stock trades at Alkermes plc and Flexion Therapeutics Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
26 May 2020 Mark Stejbach
Director
Buy 2,051 $9.75 $19,997
26 May 2020
2,051
16 Jun 2017 Mark Stejbach
Director
Buy 1,580 $17.02 $26,892
16 Jun 2017
1,580
1 Mar 2018 Mark Stejbach
Chief Commercial Officer
Option 8,063 $57.41 $462,897
1 Mar 2018
52,316
23 Feb 2018 Mark Stejbach
Chief Commercial Officer
Option 2,625 $58.60 $153,825
23 Feb 2018
47,754
16 Feb 2018 Mark Stejbach
Chief Commercial Officer
Option 13,880 $13.56 $188,213
16 Feb 2018
47,013
8 Jun 2017 Mark Stejbach
Chief Commercial Officer
Option 10,000 $17.30 $173,000
8 Jun 2017
54,013
28 May 2017 Mark Stejbach
Chief Commercial Officer
Option 2,500 $57.70 $144,250
28 May 2017
44,013
3 Mar 2017 Mark Stejbach
Chief Commercial Officer
Option 2,812 $60.97 $171,448
3 Mar 2017
41,513
1 Mar 2017 Mark Stejbach
Chief Commercial Officer
Option 5,250 $59.71 $313,478
1 Mar 2017
41,138
26 Feb 2017 Mark Stejbach
Chief Commercial Officer
Option 2,625 $52.98 $139,073
26 Feb 2017
36,740
9 Jan 2017 Mark Stejbach
Chief Commercial Officer
Option 547 $17.30 $9,463
9 Jan 2017
34,662
4 Jan 2017 Mark Stejbach
Chief Commercial Officer
Option 9,453 $17.30 $163,537
4 Jan 2017
40,768
10 Nov 2016 Mark Stejbach
Chief Commercial Officer
Option 5,780 $17.30 $99,994
10 Nov 2016
35,807
5 Oct 2016 Mark Stejbach
Chief Commercial Officer
Option 5,000 $46.43 $232,150
5 Oct 2016
31,650
28 May 2016 Mark Stejbach
Chief Commercial Officer
Option 2,500 $46.13 $115,325
28 May 2016
26,650
3 Mar 2016 Mark Stejbach
Chief Commercial Officer
Option 2,813 $32.91 $92,576
3 Mar 2016
24,150
26 Feb 2016 Mark Stejbach
Chief Commercial Officer
Option 2,625 $33.61 $88,226
26 Feb 2016
22,189
28 Dec 2015 Mark Stejbach
Chief Commercial Officer
Option 10,000 $17.30 $173,000
28 Dec 2015
29,564
1 Dec 2015 Mark Stejbach
Chief Commercial Officer
Option 18,000 $17.30 $311,400
1 Dec 2015
37,564
2 Nov 2015 Mark Stejbach
Chief Commercial Officer
Option 18,000 $17.30 $311,400
2 Nov 2015
37,964
28 May 2015 Mark Stejbach
Chief Commercial Officer
Option 2,500 $59.92 $149,800
28 May 2015
17,453
15 Apr 2015 Mark Stejbach
Chief Commercial Officer
Option 5,780 $17.30 $99,994
15 Apr 2015
16,544
3 Mar 2015 Mark Stejbach
Chief Commercial Officer
Option 2,812 $72.80 $204,714
3 Mar 2015
11,678
28 May 2014 Mark Stejbach
Chief Commercial Officer
Option 2,500 $45.74 $114,350
28 May 2014
9,680
15 Jan 2014 Mark Stejbach
Chief Commercial Officer
Option 2,780 $17.30 $48,094
15 Jan 2014
7,180
26 Dec 2013 Mark Stejbach
Chief Commercial Officer
Option 3,000 $17.30 $51,900
26 Dec 2013
4,400
13 Nov 2012 Mark Stejbach
Chief Commercial Officer
Buy 1,200 $20.13 $24,156
13 Nov 2012
1,400


Flexion Therapeutics Inc executives and stock owners

Flexion Therapeutics Inc executives and other stock owners filed with the SEC include: